Status:
COMPLETED
Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?
Lead Sponsor:
A. D. Struthers
Conditions:
Kidney Disease
Left Ventricular Hypertrophy
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Cardiovascular related disease is the main cause of death in patients with kidney disease, and "oxidative stress" is thought to be a major contributor by promoting thickening of the heart muscle and s...
Eligibility Criteria
Inclusion
- CKD stage 3
- Echo LVH
Exclusion
- Known heart failure
- Patients already on Allopurinol
- Patients with gout
- Patients with hepatic disease
- Contraindications to MRI, including severe claustrophobia
- Current immunosuppressive therapy, chlorpropamide, theophylline, 6- mercaptopurine
- Malignancy or other life threatening disease
- Pregnancy or lactating women
- Patients unable to provide written consent
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT00688480
Start Date
January 1 2008
End Date
February 1 2010
Last Update
November 3 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Medicine and Therapeutics, Ninewells Hospital & Medical School
Dundee, United Kingdom, DD1 9SY